pH-sensitive niosomes for ATRA delivery : A promising approach to inhibit Pin1 in high-grade serous ovarian cancer
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved..
The peptidyl-prolyl cis/trans isomerase Pin1 positively regulates numerous cancer-driving pathways, and it is overexpressed in several malignancies, including high-grade serous ovarian cancer (HGSOC). The findings that all-trans retinoic acid (ATRA) induces Pin1 degradation strongly support that ATRA treatment might be a promising approach for HGSOC targeted therapy. Nevertheless, repurposing ATRA into the clinics for the treatment of solid tumors remains an unmet need mainly due to the insurgence of resistance and its ineffective delivery. In the present study, niosomes have been employed for improving ATRA delivery in HGSOC cell lines. Characterization of niosomes including hydrodynamic diameter, ζ-potential, morphology, entrapment efficiency and stability over time and in culture media was performed. Furthermore, pH-sensitiveness and ATRA release profile were investigated to demonstrate the capability of these vesicles to release ATRA in a stimuli-responsive manner. Obtained results documented a nanometric and monodispersed samples with negative ζ-potential. ATRA was efficiently entrapped, and a substantial release was observed in the presence of acidic pH (pH 5.5). Finally, unloaded niosomes showed good biocompatibility while ATRA-loaded niosomes significantly increased ATRA Pin1 inhibitory activity, which was consistent with cell growth inhibition. Taken together, ATRA-loaded niosomes might represent an appealing therapeutic strategy for HGSOC therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:649 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics - 649(2023) vom: 05. Jan., Seite 123672 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Giuli, Maria Valeria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5688UTC01R |
|---|
| Anmerkungen: |
Date Completed 20.12.2023 Date Revised 20.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijpharm.2023.123672 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365432024 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365432024 | ||
| 003 | DE-627 | ||
| 005 | 20231227134901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2023.123672 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1233.xml |
| 035 | |a (DE-627)NLM365432024 | ||
| 035 | |a (NLM)38052280 | ||
| 035 | |a (PII)S0378-5173(23)01094-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Giuli, Maria Valeria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a pH-sensitive niosomes for ATRA delivery |b A promising approach to inhibit Pin1 in high-grade serous ovarian cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2023 | ||
| 500 | |a Date Revised 20.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a The peptidyl-prolyl cis/trans isomerase Pin1 positively regulates numerous cancer-driving pathways, and it is overexpressed in several malignancies, including high-grade serous ovarian cancer (HGSOC). The findings that all-trans retinoic acid (ATRA) induces Pin1 degradation strongly support that ATRA treatment might be a promising approach for HGSOC targeted therapy. Nevertheless, repurposing ATRA into the clinics for the treatment of solid tumors remains an unmet need mainly due to the insurgence of resistance and its ineffective delivery. In the present study, niosomes have been employed for improving ATRA delivery in HGSOC cell lines. Characterization of niosomes including hydrodynamic diameter, ζ-potential, morphology, entrapment efficiency and stability over time and in culture media was performed. Furthermore, pH-sensitiveness and ATRA release profile were investigated to demonstrate the capability of these vesicles to release ATRA in a stimuli-responsive manner. Obtained results documented a nanometric and monodispersed samples with negative ζ-potential. ATRA was efficiently entrapped, and a substantial release was observed in the presence of acidic pH (pH 5.5). Finally, unloaded niosomes showed good biocompatibility while ATRA-loaded niosomes significantly increased ATRA Pin1 inhibitory activity, which was consistent with cell growth inhibition. Taken together, ATRA-loaded niosomes might represent an appealing therapeutic strategy for HGSOC therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ATRA | |
| 650 | 4 | |a Nanomedicine | |
| 650 | 4 | |a Niosomes | |
| 650 | 4 | |a Ovarian cancer | |
| 650 | 4 | |a Pin1 | |
| 650 | 4 | |a pH-sensitivity | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 650 | 7 | |a Tretinoin |2 NLM | |
| 650 | 7 | |a 5688UTC01R |2 NLM | |
| 700 | 1 | |a Hanieh, Patrizia Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Forte, Jacopo |e verfasserin |4 aut | |
| 700 | 1 | |a Fabiano, Maria Gioia |e verfasserin |4 aut | |
| 700 | 1 | |a Mancusi, Angelica |e verfasserin |4 aut | |
| 700 | 1 | |a Natiello, Bianca |e verfasserin |4 aut | |
| 700 | 1 | |a Rinaldi, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Del Favero, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Ammendolia, Maria Grazia |e verfasserin |4 aut | |
| 700 | 1 | |a Marianecci, Carlotta |e verfasserin |4 aut | |
| 700 | 1 | |a Checquolo, Saula |e verfasserin |4 aut | |
| 700 | 1 | |a Carafa, Maria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics |d 1992 |g 649(2023) vom: 05. Jan., Seite 123672 |w (DE-627)NLM07779785X |x 1873-3476 |7 nnns |
| 773 | 1 | 8 | |g volume:649 |g year:2023 |g day:05 |g month:01 |g pages:123672 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpharm.2023.123672 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 649 |j 2023 |b 05 |c 01 |h 123672 | ||